Financial Performance - The company's operating revenue for Q1 2025 was ¥93,241,595.44, a decrease of 19.71% compared to ¥116,124,860.44 in the same period last year[4] - The net profit attributable to shareholders was -¥24,008,215.62, representing a decline of 574.96% from a profit of ¥5,054,819.80 in the previous year[4] - Net profit for Q1 2025 was a loss of ¥24,566,770.04, compared to a profit of ¥3,530,809.12 in Q1 2024, representing a significant decline[16] - The company reported a total comprehensive loss of ¥24,249,332.36 for Q1 2025, compared to a comprehensive income of ¥3,530,809.12 in Q1 2024[16] - Basic and diluted earnings per share were both -¥0.26, a decline of 533.33% from ¥0.06 in the same period last year[4] - Basic and diluted earnings per share for Q1 2025 were both -¥0.26, down from ¥0.06 in Q1 2024[17] Cash Flow and Liquidity - The net cash flow from operating activities was -¥9,857,827.91, an improvement of 29.62% compared to -¥14,007,005.61 in the same period last year[4] - Cash flow from operating activities for Q1 2025 was a net outflow of ¥9,857,827.91, an improvement from a net outflow of ¥14,007,005.61 in Q1 2024[17] - Cash and cash equivalents decreased to CNY 179,150,227.74 from CNY 270,149,505.21, representing a decline of approximately 33.73%[12] - Cash and cash equivalents at the end of Q1 2025 were ¥179,143,652.74, down from ¥234,606,511.59 at the end of Q1 2024[18] - Investment activities resulted in a net cash outflow of ¥60,210,905.55 in Q1 2025, compared to a net inflow of ¥63,265,564.93 in Q1 2024[18] - Financing activities led to a net cash outflow of ¥21,661,165.53 in Q1 2025, compared to a net outflow of ¥86,960,469.79 in Q1 2024[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,271,800,843.47, a decrease of 1.63% from ¥3,325,861,626.00 at the end of the previous year[5] - The company's current assets totaled CNY 1,469,794,285.16, an increase of 13.73% compared to CNY 1,292,423,310.23 at the end of 2024[13] - The company's total liabilities increased to CNY 289,666,459.87 from CNY 251,766,081.35, marking an increase of about 15.04%[14] - The total equity attributable to shareholders decreased to CNY 2,984,120,971.24 from CNY 3,075,526,738.85, a decline of approximately 2.97%[14] - The total non-current assets decreased to CNY 1,802,006,558.31 from CNY 2,033,438,315.77, reflecting a decline of approximately 11.37%[13] Operational Metrics - Research and development expenses totaled ¥20,426,393.23, accounting for 21.91% of operating revenue, an increase of 2.39 percentage points from 19.52%[5] - The decline in net profit was primarily due to a decrease in operating revenue and changes in product mix, leading to reduced gross profit[7] - The accounts receivable rose to CNY 113,821,794.92, up from CNY 91,877,262.84, indicating a growth of about 23.87%[12] - The company's inventory slightly decreased to CNY 80,360,959.86 from CNY 83,454,876.76, a reduction of approximately 3.36%[13] - The company reported a decrease in employee compensation payable to CNY 15,665,780.79 from CNY 20,364,491.39, a reduction of about 22.93%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,662[9]
热景生物(688068) - 2025 Q1 - 季度财报